iLite® ADCC Effector (V) Assay Ready Cells

Add to my product list

iLite® ADCC Effector (V) Assay Ready Cells are based on a human T lymphocyte cell line, Jurkat (ATCC #TIB-152), and have been genetically engineered and optimized to express high levels of the low affinity Fc receptor FcRyIIIa (CD16), and the Firefly Luciferase (FL) reporter gene under the control of a proprietary chimeric promoter. The FcRyIIIa receptor responds to ligation of the Fc moiety of an antibody bound to the specific antigen on target cells by activation of the FL reporter gene. 
Normalization of cell counts, serum matrix effects or lysis of the effector cells by the target cells is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promotor. 

Product code
Assay Ready Cells
Detection system
Research use only

The iLite® ADCC Effector (V) Assay Ready Cells can be used together with matched iLite ADCC Assay Ready Cells for various different targets for the quantification ADCC activity. 

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell (1). 
The idea of employing ADCC to destroy dysfunctional cells by treating patients with antibodies which induce this mechanism has existed since the discovery of the ADCC mechanism. The first monoclonal antibody for treating cancer to be FDA approved was Rituximab which in part utilizes the ADCC mechanism to destroy cancer cells expressing CD20. Induction of ADCC through monoclonal antibodies is also utilized in treating autoimmune diseases (2, 3). 


  1. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 15: 361-70 (2015).
  2. Grillo-López AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma, Semin Oncol 26:66-73 (1999).
  3. Brennan FR, Morton LD, Spindeldreher S, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies, MAbs, 2:233-55 (2010). 

>250 µL of iLite® Assay Ready Cells suspended in RPMI 1640 with 20% heat inactivated fetal bovine serum (FBS), mixed 1:1 with cryoprotective medium from Lonza (Cat. No 12-132A).